High expression of PD-1 and PD-L1 in ocular adnexal sebaceous carcinoma

Ocular adnexal sebaceous carcinoma (OASC) is an aggressive malignancy that frequently recurs locally and metastasizes. Surgical extirpation may produce significant aesthetic morbidity, and effective systemic therapies for locally advanced or metastatic disease are largely ineffective. Immune checkpo...

Full description

Saved in:

Bibliographic Details
Published in:	Oncoimmunology Vol. 7; no. 9; p. e1475874
Main Authors:	Kandl, Thomas J., Sagiv, Oded, Curry, Jonathan L., Ning, Jing, Ma, Junsheng, Hudgens, Courtney W., Van Arnam, John, Wargo, Jennifer A., Esmaeli, Bita, Tetzlaff, Michael T.
Format:	Journal Article
Language:	English
Published:	United States Taylor & Francis 02.09.2018 Taylor & Francis Group
Subjects:	biomarkers carcinoma immunosurveillance inflammation and cancer ocular Original Research PD-1 PD-L1 Sebaceous carcinoma biomarkers inflammation and cancer PD-L1 Sebaceous PD-1 immunosurveillance ocular
ISSN:	2162-402X, 2162-4011, 2162-402X
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Ocular adnexal sebaceous carcinoma (OASC) is an aggressive malignancy that frequently recurs locally and metastasizes. Surgical extirpation may produce significant aesthetic morbidity, and effective systemic therapies for locally advanced or metastatic disease are largely ineffective. Immune checkpoint inhibitors have shown efficacy in the management of several solid tumors where tumor cell PD-L1 expression correlates with improved response. To determine whether OASC might be amenable to immune checkpoint blockade, we performed comprehensive immune profiling for CD3, CD8, PD-1, FOXP3, and PD-L1 in 24 patients with primary OASC. The composition, distribution and density of the tumor associated immune infiltrate were quantified by automated image analysis and correlated with measures of clinical outcome. Tumor cells in 12 OASCs (50%) expressed PD-L1. Higher densities of CD3+ (p = 0.01), CD8+ (p = 0.006), and PD-1+ (p = 0.024) tumor-associated T cells were associated with higher T category (≥T3a per the 7th edition of the American Joint Committee on Cancer staging manual). Higher tumor cell expression of PD-L1 correlated with higher density of PD-1+ tumor-associated T cells (p = 0.021). Since a CD3+ CD8+ PD-1 + T-cell infiltrate represents a "suppressed T-cell phenotype" apparently permissive toward OASC progression, our findings provide a mechanistic rationale for the effective application of immune checkpoint blockade in OASC to abrogate PD-1/PD-L1 interaction and effectively unleash the immune infiltrate to treat higher-stage tumors.
AbstractList	Ocular adnexal sebaceous carcinoma (OASC) is an aggressive malignancy that frequently recurs locally and metastasizes. Surgical extirpation may produce significant aesthetic morbidity, and effective systemic therapies for locally advanced or metastatic disease are largely ineffective. Immune checkpoint inhibitors have shown efficacy in the management of several solid tumors where tumor cell PD-L1 expression correlates with improved response. To determine whether OASC might be amenable to immune checkpoint blockade, we performed comprehensive immune profiling for CD3, CD8, PD-1, FOXP3, and PD-L1 in 24 patients with primary OASC. The composition, distribution and density of the tumor associated immune infiltrate were quantified by automated image analysis and correlated with measures of clinical outcome. Tumor cells in 12 OASCs (50%) expressed PD-L1. Higher densities of CD3+ (p = 0.01), CD8+ (p = 0.006), and PD-1+ (p = 0.024) tumor-associated T cells were associated with higher T category (≥T3a per the 7th edition of the American Joint Committee on Cancer staging manual). Higher tumor cell expression of PD-L1 correlated with higher density of PD-1+ tumor-associated T cells (p = 0.021). Since a CD3+ CD8+ PD-1 + T-cell infiltrate represents a “suppressed T-cell phenotype” apparently permissive toward OASC progression, our findings provide a mechanistic rationale for the effective application of immune checkpoint blockade in OASC to abrogate PD-1/PD-L1 interaction and effectively unleash the immune infiltrate to treat higher-stage tumors. Ocular adnexal sebaceous carcinoma (OASC) is an aggressive malignancy that frequently recurs locally and metastasizes. Surgical extirpation may produce significant aesthetic morbidity, and effective systemic therapies for locally advanced or metastatic disease are largely ineffective. Immune checkpoint inhibitors have shown efficacy in the management of several solid tumors where tumor cell PD-L1 expression correlates with improved response. To determine whether OASC might be amenable to immune checkpoint blockade, we performed comprehensive immune profiling for CD3, CD8, PD-1, FOXP3, and PD-L1 in 24 patients with primary OASC. The composition, distribution and density of the tumor associated immune infiltrate were quantified by automated image analysis and correlated with measures of clinical outcome. Tumor cells in 12 OASCs (50%) expressed PD-L1. Higher densities of CD3+ (p = 0.01), CD8+ (p = 0.006), and PD-1+ (p = 0.024) tumor-associated T cells were associated with higher T category (≥T3a per the 7th edition of the American Joint Committee on Cancer staging manual). Higher tumor cell expression of PD-L1 correlated with higher density of PD-1+ tumor-associated T cells (p = 0.021). Since a CD3+ CD8+ PD-1 + T-cell infiltrate represents a "suppressed T-cell phenotype" apparently permissive toward OASC progression, our findings provide a mechanistic rationale for the effective application of immune checkpoint blockade in OASC to abrogate PD-1/PD-L1 interaction and effectively unleash the immune infiltrate to treat higher-stage tumors.Ocular adnexal sebaceous carcinoma (OASC) is an aggressive malignancy that frequently recurs locally and metastasizes. Surgical extirpation may produce significant aesthetic morbidity, and effective systemic therapies for locally advanced or metastatic disease are largely ineffective. Immune checkpoint inhibitors have shown efficacy in the management of several solid tumors where tumor cell PD-L1 expression correlates with improved response. To determine whether OASC might be amenable to immune checkpoint blockade, we performed comprehensive immune profiling for CD3, CD8, PD-1, FOXP3, and PD-L1 in 24 patients with primary OASC. The composition, distribution and density of the tumor associated immune infiltrate were quantified by automated image analysis and correlated with measures of clinical outcome. Tumor cells in 12 OASCs (50%) expressed PD-L1. Higher densities of CD3+ (p = 0.01), CD8+ (p = 0.006), and PD-1+ (p = 0.024) tumor-associated T cells were associated with higher T category (≥T3a per the 7th edition of the American Joint Committee on Cancer staging manual). Higher tumor cell expression of PD-L1 correlated with higher density of PD-1+ tumor-associated T cells (p = 0.021). Since a CD3+ CD8+ PD-1 + T-cell infiltrate represents a "suppressed T-cell phenotype" apparently permissive toward OASC progression, our findings provide a mechanistic rationale for the effective application of immune checkpoint blockade in OASC to abrogate PD-1/PD-L1 interaction and effectively unleash the immune infiltrate to treat higher-stage tumors.
Author	Ning, Jing Ma, Junsheng Sagiv, Oded Curry, Jonathan L. Wargo, Jennifer A. Hudgens, Courtney W. Tetzlaff, Michael T. Van Arnam, John Kandl, Thomas J. Esmaeli, Bita
Author_xml	– sequence: 1 givenname: Thomas J. surname: Kandl fullname: Kandl, Thomas J. organization: Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center – sequence: 2 givenname: Oded orcidid: 0000-0003-0563-278X surname: Sagiv fullname: Sagiv, Oded organization: Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center – sequence: 3 givenname: Jonathan L. surname: Curry fullname: Curry, Jonathan L. organization: Department of Dermatology, The University of Texas MD Anderson Cancer Center – sequence: 4 givenname: Jing surname: Ning fullname: Ning, Jing organization: Department of Biostatistics, The University of Texas MD Anderson Cancer Center – sequence: 5 givenname: Junsheng surname: Ma fullname: Ma, Junsheng organization: Department of Biostatistics, The University of Texas MD Anderson Cancer Center – sequence: 6 givenname: Courtney W. orcidid: 0000-0001-8312-7485 surname: Hudgens fullname: Hudgens, Courtney W. organization: Department of Translational and Molecular Pathology, The University of Texas MD Anderson Cancer Center – sequence: 7 givenname: John surname: Van Arnam fullname: Van Arnam, John organization: Department of Pathology, Section of Dermatopathology, The University of Texas MD Anderson Cancer Center – sequence: 8 givenname: Jennifer A. surname: Wargo fullname: Wargo, Jennifer A. organization: Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center – sequence: 9 givenname: Bita surname: Esmaeli fullname: Esmaeli, Bita email: besmaeli@mdanderson.org, mtetzlaff@mdanderson.org organization: Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center – sequence: 10 givenname: Michael T. surname: Tetzlaff fullname: Tetzlaff, Michael T. organization: Department of Translational and Molecular Pathology, The University of Texas MD Anderson Cancer Center
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/30228943$$D View this record in MEDLINE/PubMed
BookMark	eNqFUU1v1DAQtVARLaU_AZQjlyz-StYREqIq0FZaCQ4gcbMm9mTryrEXOwvtv8dht1XLAebi-Xjvje33nByEGJCQl4wuGFX0DWctl5R_X3DK1ILJZaOW8gk5mvv1PDh4kB-Sk5yvaYmWNq3onpFDQTlXnRRH5PzCra8qvNkkzNnFUMWh-vKhZhUEOycrVrnSNFsPqQIb8AZ8lbEHg3GbKwPJuBBHeEGeDuAznuzPY_Lt08evZxf16vP55dnpqjaNkFMNTcutlNww2wkAUD1Yqnjf8SV2VghLW44DDhZ73tOeUQ4Cl9J2vJRWWXFMLne6NsK13iQ3QrrVEZz-04hprSFNznjUXDRSAhc9lVaWh_cIDDshkXeAoGTRerfT2mz7Ea3BMCXwj0QfT4K70uv4U7dM0kY1ReD1XiDFH1vMkx5dNug9hPl3NGclGi46UaCvHu66X3LnRAE0O4BJMeeEwz2EUT2bru9M17Ppem964b39i2fcBFOxslzZ-f-y3-_YLgwxjfArJm_1BLc-piFBMC5r8W-J39-4xAc
CitedBy_id	crossref_primary_10_1097_IIO_0000000000000271 crossref_primary_10_3892_ol_2024_14726 crossref_primary_10_1016_j_ajo_2020_07_031 crossref_primary_10_1111_cup_14579 crossref_primary_10_3389_fmed_2019_00160 crossref_primary_10_1016_j_ejca_2025_115403 crossref_primary_10_1016_S1470_2045_19_30673_4 crossref_primary_10_1097_IOP_0000000000001585 crossref_primary_10_1136_bjo_2024_326923 crossref_primary_10_1007_s00262_020_02821_3 crossref_primary_10_1080_08820538_2019_1620813 crossref_primary_10_1007_s11912_021_01120_z crossref_primary_10_1097_IIO_0000000000000309 crossref_primary_10_1016_j_jaad_2020_03_131 crossref_primary_10_1007_s00432_023_04629_x crossref_primary_10_1080_08820538_2025_2458658 crossref_primary_10_1097_IOP_0000000000001472 crossref_primary_10_1136_bjophthalmol_2019_315490 crossref_primary_10_1158_1078_0432_CCR_21_2971 crossref_primary_10_1111_ddg_15405_g crossref_primary_10_1111_ajd_13919 crossref_primary_10_1111_ddg_15405 crossref_primary_10_1167_iovs_19_26894 crossref_primary_10_3390_biom13060991
Cites_doi	10.1016/0190-9622(95)90001-2 10.1097/IOP.0b013e31816d925f 10.1111/ijd.2017.56.issue-7 10.1126/scitranslmed.3003689 10.1016/j.preteyeres.2009.06.002 10.1016/j.immuni.2007.05.016 10.1093/intimm/dxw021 10.1158/1078-0432.CCR-13-3271 10.1016/S0046-8177(82)80115-9 10.1038/nature13954 10.1038/modpathol.2017.156 10.1200/JCO.2010.30.6308 10.1158/1078-0432.CCR-11-3020 10.1056/NEJMoa1504030 10.1016/j.sjopt.2013.05.002 10.1158/1078-0432.CCR-16-0392 10.1309/AJCPIKDZM39CRPNC 10.1016/j.ctrv.2015.11.001 10.1016/j.jaad.2009.04.058 10.1111/ijd.2011.50.issue-12 10.1002/path.4287 10.1016/S1470-2045(15)70076-8 10.1186/s13045-016-0277-y 10.1097/PPO.0000000000000301 10.1002/path.4759 10.1016/j.ajo.2013.08.015 10.1097/APO.0000000000000105 10.1167/iovs.11-9280 10.1038/nri1349 10.1097/QAD.0b013e3283213046 10.1126/science.aaf1490 10.1016/S1470-2045(16)30364-3 10.1126/science.1129139 10.1200/JCO.2010.30.5425 10.1097/IOP.0b013e31827472c5 10.1016/j.ophtha.2011.11.006 10.1056/NEJMoa1305133 10.1158/2159-8290.CD-15-1545 10.1200/JCO.2014.56.2736 10.1016/j.ophtha.2004.07.031 10.1002/cncr.23952 10.1038/nature14011 10.1056/NEJMoa1603702 10.1016/S0161-6420(01)00719-9 10.1158/1078-0432.CCR-16-1821
ContentType	Journal Article
Copyright	2018 Taylor & Francis Group, LLC 2018 2018 Taylor & Francis Group, LLC 2018 Taylor & Francis
Copyright_xml	– notice: 2018 Taylor & Francis Group, LLC 2018 – notice: 2018 Taylor & Francis Group, LLC 2018 Taylor & Francis
DBID	AAYXX CITATION NPM 7X8 5PM DOA
DOI	10.1080/2162402X.2018.1475874
DatabaseName	CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals
DatabaseTitle	CrossRef PubMed MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic PubMed
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Biology
DocumentTitleAlternate	T. J. KANDL ET AL
EISSN	2162-402X
ExternalDocumentID	oai_doaj_org_article_23544a23b04d4563bea1e934e29aea84 PMC6140585 30228943 10_1080_2162402X_2018_1475874 1475874
Genre	Original Article Journal Article
GroupedDBID	00X 0YH 53G AAKDD ABUPF ACGFS ADBBV ADCVX AENEX AIJEM ALMA_UNASSIGNED_HOLDINGS AOIJS AQTUD BABNJ BLEHA CCCUG DEAQA DGEBU DGFLZ EBS EJD EMOBN EUPTU GROUPED_DOAJ H13 HYE KRBQP KSSTO KTTOD KWAYT KYCEM M4Z O9- OK1 RPM TDBHL TFL TFW TNTFI TTHFI AAYXX CITATION 4.4 ABDBF ACUHS EBD LJTGL NPM OVD TEORI 7X8 5PM
ID	FETCH-LOGICAL-c534t-a562d442c1d93aaa8bad082b927e9d33d062efefdeb2b0b102a3e74d922b0d8d3
IEDL.DBID	TFW
ISICitedReferencesCount	25
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000443993100019&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	2162-402X 2162-4011
IngestDate	Fri Oct 03 12:42:07 EDT 2025 Tue Nov 04 02:05:22 EST 2025 Thu Oct 02 09:47:59 EDT 2025 Thu Apr 03 06:57:57 EDT 2025 Sat Nov 29 03:25:35 EST 2025 Tue Nov 18 20:43:02 EST 2025 Mon Oct 20 23:49:31 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	9
Keywords	carcinoma biomarkers inflammation and cancer PD-L1 Sebaceous PD-1 immunosurveillance ocular
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c534t-a562d442c1d93aaa8bad082b927e9d33d062efefdeb2b0b102a3e74d922b0d8d3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally to this work. Color versions of one or more of the figures in the article can be found online at www.tandfonline.com/koni.
ORCID	0000-0003-0563-278X 0000-0001-8312-7485
OpenAccessLink	https://doaj.org/article/23544a23b04d4563bea1e934e29aea84
PMID	30228943
PQID	2111152393
PQPubID	23479
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_6140585 doaj_primary_oai_doaj_org_article_23544a23b04d4563bea1e934e29aea84 informaworld_taylorfrancis_310_1080_2162402X_2018_1475874 crossref_citationtrail_10_1080_2162402X_2018_1475874 crossref_primary_10_1080_2162402X_2018_1475874 proquest_miscellaneous_2111152393 pubmed_primary_30228943
PublicationCentury	2000
PublicationDate	2018-09-02
PublicationDateYYYYMMDD	2018-09-02
PublicationDate_xml	– month: 09 year: 2018 text: 2018-09-02 day: 02
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Oncoimmunology
PublicationTitleAlternate	Oncoimmunology
PublicationYear	2018
Publisher	Taylor & Francis Taylor & Francis Group
Publisher_xml	– name: Taylor & Francis – name: Taylor & Francis Group
References	CIT0030 CIT0010 CIT0032 CIT0031 CIT0012 CIT0034 CIT0011 CIT0033 CIT0014 CIT0036 CIT0013 CIT0035 CIT0016 CIT0038 CIT0015 CIT0037 CIT0018 CIT0017 CIT0039 CIT0019 CIT0041 CIT0040 CIT0021 CIT0043 CIT0020 CIT0042 CIT0001 CIT0023 CIT0045 CIT0022 CIT0044 Edge S (CIT0047) 2009 CIT0003 CIT0025 CIT0002 CIT0024 CIT0046 CIT0005 CIT0027 CIT0004 CIT0026 CIT0007 CIT0029 CIT0006 CIT0009 CIT0008
References_xml	– ident: CIT0005 doi: 10.1016/0190-9622(95)90001-2 – ident: CIT0009 doi: 10.1097/IOP.0b013e31816d925f – ident: CIT0026 doi: 10.1111/ijd.2017.56.issue-7 – ident: CIT0040 doi: 10.1126/scitranslmed.3003689 – ident: CIT0045 doi: 10.1016/j.preteyeres.2009.06.002 – ident: CIT0013 doi: 10.1016/j.immuni.2007.05.016 – ident: CIT0042 doi: 10.1093/intimm/dxw021 – ident: CIT0029 doi: 10.1158/1078-0432.CCR-13-3271 – ident: CIT0010 doi: 10.1016/S0046-8177(82)80115-9 – ident: CIT0023 doi: 10.1038/nature13954 – volume-title: AJCC cancer staging handbook year: 2009 ident: CIT0047 – ident: CIT0031 doi: 10.1038/modpathol.2017.156 – ident: CIT0021 doi: 10.1200/JCO.2010.30.6308 – ident: CIT0022 doi: 10.1158/1078-0432.CCR-11-3020 – ident: CIT0035 doi: 10.1056/NEJMoa1504030 – ident: CIT0001 doi: 10.1016/j.sjopt.2013.05.002 – ident: CIT0030 doi: 10.1158/1078-0432.CCR-16-0392 – ident: CIT0020 doi: 10.1309/AJCPIKDZM39CRPNC – ident: CIT0019 doi: 10.1016/j.ctrv.2015.11.001 – ident: CIT0006 doi: 10.1016/j.jaad.2009.04.058 – ident: CIT0027 doi: 10.1111/ijd.2011.50.issue-12 – ident: CIT0038 doi: 10.1002/path.4287 – ident: CIT0033 doi: 10.1016/S1470-2045(15)70076-8 – ident: CIT0018 doi: 10.1186/s13045-016-0277-y – ident: CIT0024 doi: 10.1097/PPO.0000000000000301 – ident: CIT0046 doi: 10.1002/path.4759 – ident: CIT0003 doi: 10.1016/j.ajo.2013.08.015 – ident: CIT0004 doi: 10.1097/APO.0000000000000105 – ident: CIT0043 doi: 10.1167/iovs.11-9280 – ident: CIT0014 doi: 10.1038/nri1349 – ident: CIT0025 doi: 10.1097/QAD.0b013e3283213046 – ident: CIT0044 doi: 10.1126/science.aaf1490 – ident: CIT0032 doi: 10.1016/S1470-2045(16)30364-3 – ident: CIT0037 doi: 10.1126/science.1129139 – ident: CIT0041 doi: 10.1200/JCO.2010.30.5425 – ident: CIT0002 doi: 10.1097/IOP.0b013e31827472c5 – ident: CIT0012 doi: 10.1016/j.ophtha.2011.11.006 – ident: CIT0016 doi: 10.1056/NEJMoa1305133 – ident: CIT0036 doi: 10.1158/2159-8290.CD-15-1545 – ident: CIT0015 doi: 10.1200/JCO.2014.56.2736 – ident: CIT0008 doi: 10.1016/j.ophtha.2004.07.031 – ident: CIT0007 doi: 10.1002/cncr.23952 – ident: CIT0034 doi: 10.1038/nature14011 – ident: CIT0017 doi: 10.1056/NEJMoa1603702 – ident: CIT0011 doi: 10.1016/S0161-6420(01)00719-9 – ident: CIT0039 doi: 10.1158/1078-0432.CCR-16-1821
SSID	ssj0000605639
Score	2.3013482
Snippet	Ocular adnexal sebaceous carcinoma (OASC) is an aggressive malignancy that frequently recurs locally and metastasizes. Surgical extirpation may produce...
SourceID	doaj pubmedcentral proquest pubmed crossref informaworld
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	e1475874
SubjectTerms	biomarkers carcinoma immunosurveillance inflammation and cancer ocular Original Research PD-1 PD-L1 Sebaceous
SummonAdditionalLinks	– databaseName: Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYhNJBL6SvtNm1RIVcntiTb0rGvtIcSckhhb2IkjchCqy3ZTUn_fUayd9kNhb3UJ1sPI41Gmk_W-BvGTroAUKtIM00LrFQX2wq0lLQYRtSt0U63oQSb6C8u9HRqLjdCfWWfsIEeeBDcmZCtUiCkq1UgYy8dQoNGKhQGEHRhAiXUs7GZGtZgMuzSrH7Z0fWZaLp8kDDN3lya1gfCyb3aMkaFs_8BY-m_cOdD98kNe3T-hD0egST_MHTgKdvD9IwdDKEl_z5nX7MDB8e70c818Xnkl5-rhkMK-eZ7w2eUWLxQOYSEd_SyBTrwOL9dcJ9DDKX5L3jBfpx_ufr0rRqDJlS-lWpZAQGaoJTwTTASALSDQGbeGdGjCVKGuhMYMQbaUrvaEb4Aib0KRtBj0EEesf00T_iKcSRLFR0SYqNNU91Fgg6-a0E02BnvMUyYWknP-pFRPAe2-GmbkXh0JXSbhW5HoU_Y6bra74FSY1eFj3lo1oUzI3ZJID2xo57YXXoyYWZzYO2yfBCJQ_QSK3c04P1KCyzNvnykAimPBhWnq800chP2ctCKdTNlphYyinL6LX3Z6sd2TppdF4Zvwkw17eNe_4-OH7PD3JfiFyfesP3lzS2-ZY_8n-VscfOuTJt7v-wV9A priority: 102 providerName: Directory of Open Access Journals
Title	High expression of PD-1 and PD-L1 in ocular adnexal sebaceous carcinoma
URI	https://www.tandfonline.com/doi/abs/10.1080/2162402X.2018.1475874 https://www.ncbi.nlm.nih.gov/pubmed/30228943 https://www.proquest.com/docview/2111152393 https://pubmed.ncbi.nlm.nih.gov/PMC6140585 https://doaj.org/article/23544a23b04d4563bea1e934e29aea84
Volume	7
WOSCitedRecordID	wos000443993100019&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAWR databaseName: Taylor and Francis Online Journals customDbUrl: eissn: 2162-402X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000605639 issn: 2162-402X databaseCode: TFW dateStart: 20180102 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis – providerCode: PRVAWR databaseName: Taylor and Francis Online Journals customDbUrl: eissn: 2162-402X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000605639 issn: 2162-402X databaseCode: TFW dateStart: 20120101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELWgAokL5ZstsDIS10BiO4l9bIGFA6p6KGJv1jgew0olQZstKv-esZOsuhWoB8gpiePEHzPxs_PyhrFXlQfIVSBP0wIzVYUyAy0lvQwD6tJop0ufgk3Ux8d6uTQnI5uwH2mVcQ4dBqGI9K6Ozg2unxhxb0RRxW8Cy0jM0uTqBHnrqAhKyD7a-Oniy3aVJSe0TmPw9OvO3zLvDEpJu_-Kcumf8OdVGuWlcWmx_x9qdI_dHUEpPxys6D67ge0DdnsIU_nrIfsQySAcL0bObMu7wE_eZQWn58WdTwVf0cnEaOXgW7ygm_XooMHuvOdNDFfUdt_hEfu8eH_69mM2BmDImlKqTQYEjrxSoim8kQCgHXiCDM6IGo2X0ueVwIDB0_Tc5Y6wCkislTeCDr328jHba7sWnzKONOoFh4T-aAKWV4FgSFOVIAqsTNOgnzE19YBtRnXyGCTjzBajiOnURja2kR3baMZeb7P9GOQ5rstwFLt3e3FU104nuvVXOzqrFbJUCoR0ufIEMKVDKNBIhcIAgqabmMvGYTdpcSUMkVCsvKYALydLsuTJ8fMMtLE36HLayihJN2NPBsvaFlNGmSKjKKXesbmdeuymtKtvSS2c8FdOc8KDfyjzM3YnHiZqnXjO9jbrc3zBbjU_N6t-PWc366Wep8WMefK-3-ehKOw
linkProvider	Taylor & Francis
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELZgAbEX3o_yNBLXsIntJPaRV1lEqTgU0Zvl2GOoBAlqu6vdf78zeVTtCrQHyKmJ49SxZzKfnS_fMPayCM6lKqKnaQGJKmKeOC0lPgwj6NzoSuehTTZRTqd6Pjfb38IQrZLm0LETimif1eTctBg9UOIORFbQS4E5MbM0-jpi3lJdZldyjLVE65uNv23WWVLE6xiFh493_lZ7Jyy16v3ntEv_hEDPEym3ItP45v-4p1vsRo9L-evOkG6zS1DfYde6TJWnd9kH4oNwOOlpszVvIv_yLsk4_iH9mGR8gQdbUit3oYYTvNgKKuehOVpxTxmL6uaXu8e-jt_P3h4mfQ6GxOdSrROH-CgoJXwWjHTO6coFRA2VESWYIGVICwERYsAZepVWCFechFIFI3A36CDvs726qeEh44CBL1aAABDnYGkREYn4Incig8J4D2HE1DAE1vcC5ZQn46fNeh3ToY8s9ZHt-2jEXm2q_e4UOi6q8IbGd3MyCWy3B5rld9v7qxUyV8oJWaUqIMaUFbgMjFQgjAOn8SJm2zrsul1fiV0yFCsvaMCLwZQsOjO9oXE1jQaejltOqnQj9qAzrU0zJSkVGYUl5Y7R7dzHbkm9-NEKhiMES3Fa-Ogf2vycXT-cfZ7Yycfpp8dsn4papp14wvbWyyN4yq764_VitXzWut8Zh3YrMA
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Jj9MwFLZgWMSFfSmrkbgGEttJ7CMwFBCjqodB9GZ5eYZKkIzaDhr-Pc-OU01HoDlATkkcJ17eiz_HX75HyIvGG1OKgJ4mGRSiCXVhJOf4MgwgayWtrH0KNtHOZnKxUPPMJlxnWmWcQ4dBKCK9q6NzH_kwMuJesaqJawKLSMyS6OoIeVtxkVxK4lho0ofTL9vPLCXCdRyEx393_pZ7Z1RK4v1npEv_BEDP8ihPDUzTG_-hSjfJ9YxK6evBjG6RC9DdJleGOJW_7pD3kQ1C4SSTZjvaBzrfLyqKz4s7BxVd4slEaaXGd3CCN1uDNQ764zV1MV5R1_8wd8nn6bvDtx-KHIGhcDUXm8IgOvJCMFd5xY0x0hqPmMEq1oLynPuyYRAgeJyf29IiWDEcWuEVw0MvPb9H9rq-gweEAg57wQLCP5yBlU1AHOKa2rAKGuUc-AkRYw9ol-XJY5SM77rKKqZjG-nYRjq30YS83GY7GvQ5zsvwJnbv9uIor51O9KuvOnurZrwWwjBuS-ERYXILpgLFBTBlwEi8iTptHHqTvq6EIRSK5ucU4PloSRpdOa7PmC72Bl6OWx016Sbk_mBZ22LyqFOkBKa0Oza3U4_dlG75LcmFIwArcVL48B_K_Ixcne9P9cHH2adH5FpMSTQ79pjsbVbH8IRcdj83y_XqaXK-36jEKdQ
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=High+expression+of+PD-1+and+PD-L1+in+ocular+adnexal+sebaceous+carcinoma&rft.jtitle=Oncoimmunology&rft.au=Kandl%2C+Thomas+J.&rft.au=Sagiv%2C+Oded&rft.au=Curry%2C+Jonathan+L.&rft.au=Ning%2C+Jing&rft.date=2018-09-02&rft.pub=Taylor+%26+Francis&rft.eissn=2162-402X&rft.volume=7&rft.issue=9&rft_id=info:doi/10.1080%2F2162402X.2018.1475874&rft.externalDocID=1475874
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2162-402X&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2162-402X&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2162-402X&client=summon